Dengue virus
| Amiodarone | DENV-2 | Non-competitive β-adrenergic inhibitor | Preclinical | — | Human (multiple) | |
| Amodiaquine | DENV-2 | Methyltransferase inhibitor | Preclinical | — | Human HNMT | |
| Anisomycin | DENV-2 | DNA synthesis inhibitor | Preclinical | — | Human ribosome | |
| Azauridine | DENV-2 | Nucleoside analog | Preclinical | — | Viral RNA pol | |
| Bepridil | DENV-2 | Calcium / Potassium / Sodium channel antagonist | Preclinical | — | Human ion channel | |
| Betulinic Acid | DENV-2 | Unknown | Preclinical | — | Unknown | |
| Bortezomib | DENV-2 | Proteasome inhibitor (26S subunit) | Preclinical | — | Human proteasome | |
| Chlorpromazine | DENV-2 | Inhibits assembly of clathrin-coated pits at the plasma membrane | Preclinical | — | Human (multiple) | |
| Cucurbit[7]uril | DENV-2 | Competitive binding of polyamines | Preclinical | — | Human polyamines | |
| Cyclosporine | DENV-2 | Calcineurin inhibitor; allows for inhibition of T cell activation | Preclinical | — | Human CYPs | |
| Erlotinib | DENV-2 | EGFR inhibitor | Preclinical | — | Human PTK | |
| Fenretinide | DENV-2 | Unclear | Preclinical | — | Human RAR | |
| Fluoxetine | DENV-2 | Selective serotonin reuptake inhibitor | Preclinical | — | Viral ATPase/helicase | |
| Fluvastatin | DENV-2 | Hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor | Preclinical | — | Human HMGCR | |
| Galidesivir | DENV-2 | RNA-dependent RNA polymerase (RdRp) inhibitor | Preclinical | — | Viral RNA pol | |
| Glycyrrhizin | DENV-2 | 0 | Preclinical | — | Human TNF | |
| GS-441524 | DENV-2 | nucleoside analog | Preclinical | — | Viral RNA pol | |
| GSK583 | DENV-2 | Inhibition of PRR signaling | Preclinical | — | Human RIPK2 | |
| GSK717 | DENV-2 | Inhibiton of PRR signaling | Preclinical | — | Human NOD2 | |
| Halofuginone | DENV-2 | tRNA synthase inhibitor | Preclinical | — | Human (multiple) | |
| Hydroxychloroquine | DENV-2 | Unclear | Preclinical | — | Human (multiple) | |
| Itraconazole | DENV-2 | Inhibition of OSBP and ORP4; Inhibition of viral organelle formation | Preclinical | — | Human lipid transfer protein | |
| Lanatoside C | DENV-2 | Increasing the concentration of intracellular calcium | Preclinical | — | Unknown | |
| Lovastatin | DENV-2 | HMG-CoA reductase inhibitor | Preclinical | — | Human HMGCR | |
| Luteolin | DENV-2 | Unknown | Preclinical | — | Unknown |